Therapeutic Drug Monitoring 2011-04-01

The role of inosine-5'-monophosphate dehydrogenase in thiopurine metabolism in patients with inflammatory bowel disease.

Sofie Haglund, Svante Vikingsson, Jan Söderman, Ulf Hindorf, Christer Grännö, Margareta Danelius, Sally Coulthard, Curt Peterson, Sven Almer

Index: Ther. Drug Monit. 33 , 200-208, (2011)

Full Text: HTML

Abstract

There is a large interindividual variability in thiopurine metabolism. High concentrations of methylthioinosine-5'-monophosphate (meTIMP) and low concentrations of 6-thioguanine nucleotides (6-TGNs) have been associated with a lower response rate and an increased risk of adverse events. In this study, the role of inosine-5'-monophosphate dehydrogenase (IMPDH) for differences in metabolite patterns of thiopurines was investigated.IMPDH activity and thiopurine metabolite concentrations were determined in patients with inflammatory bowel disease and a normal thiopurine methyltransferase (TPMT) phenotype and meTIMP/6-TGN concentration ratio > 20 (n = 26), in patients with a metabolite ratio ≤ 20 (n = 21), in a subgroup with a metabolite ratio <4 (n = 6), and in 10 patients with reduced TPMT activity. In vitro studies were conducted on human embryonic kidney cells (HEK293) with genetically engineered IMPDH and TPMT activities.Patients with metabolite ratios >20 had lower IMPDH activity than those with ratios ≤ 20 (P < 0.001). Metabolite ratios >20 were only observed in patients with normal TPMT activity. Downregulation of IMPDH activity in HEK293 cells was associated with an increase in the concentration of meTIMP (fold change: 17 up to 93, P < 0.001) but, unexpectedly, also of 6-thioguanosine monophosphate (fold change: 2.6 up to 5.0, P < 0.001).These data question the general view of IMPDH as the rate-limiting enzyme in the phosphorylation of thiopurines. Investigations of other mechanisms are needed to more fully explain the various metabolite patterns and outcomes in patients under treatment.


Related Compounds

Related Articles:

The antibiotic potential of prokaryotic IMP dehydrogenase inhibitors.

2011-01-01

[Curr. Med. Chem. 18 , 1909-1918, (2011)]

Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on rat cardiac allograft rejection.

2013-03-01

[Int. Immunopharmacol. 10 , 91-97, (2010)]

A new class of IMP dehydrogenase with a role in self-resistance of mycophenolic acid producing fungi.

2011-01-01

[BMC Microbiol. 11 , 202, (2011)]

The Cys319 loop modulates the transition between dehydrogenase and hydrolase conformations in inosine 5'-monophosphate dehydrogenase.

2010-12-21

[Biochemistry 49 , 10674-10681, (2010)]

Guanosine supplementation reduces the antiproliferative and apoptotic effects of the IMPDH inhibitor gnidilatimonoein in K562 cells.

2011-10-01

[Cell Biol. Int. 35 , 1001-1008, (2011)]

More Articles...